Khalid Ahmed, MD
Internal Medicine · Flint, MINPI 1619965175
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,817 of the $6,652 with a category attached, or 87.4%. It is spread thinly across 44 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,942 and has fallen 70.8% since, to $567 in 2025. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- AbbVie$740
- Gilead$481
- AstraZeneca$461
- Otsuka America Pharmaceutical, Inc.$344
- Boehringer Ingelheim$315
- plus $3K from 38 others
Across 39 payments — averaging $4289.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$76K
- Novartis$57K
- Pfizer$18K
- Hikma Pharmaceuticals USA$9K
- Boehringer Ingelheim$4K
- GSK$4K
What the payments were for
- Travel & lodging$82212%
- Food & beverage$5,81787%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veklury$126
- FARXIGA$125
- INVOKANA$120
- NURTEC ODT$110
How this compares
$6,652 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $67,355 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $24,508 |
| TrulicityDulaglutide | 21 | $23,499 |
| RybelsusSemaglutide | 13 | $21,739 |
| OzempicSemaglutide | 20 | $21,054 |
| JanuviaSitagliptin Phosphate | 27 | $20,079 |
| EntrestoSacubitril/Valsartan | 21 | $16,727 |
| XareltoRivaroxaban | 22 | $16,643 |
| Atrovent HfaIpratropium Bromide | 19 | $12,575 |
| FarxigaDapagliflozin Propanediol | 15 | $8,664 |
| JardianceEmpagliflozin | 14 | $8,247 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $4,996 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,833 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 115 | $3,598 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 11 | $3,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $209 | $70,812116 claims |
| Novo NordiskRybelsus, Ozempic | $142 | $42,79333 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix | $107 | $35,38373 claims |
| Lilly USA, LLCTrulicity | $110 | $23,49921 claims |
| MerckJanuvia | $81 | $20,07927 claims |
| NovartisEntresto | $1,560 | $16,72721 claims |
| Johnson & JohnsonXarelto | $229 | $16,64322 claims |
| AstraZenecaFarxiga, Symbicort | $461 | $11,33227 claims |
| Boehringer IngelheimJardiance | $315 | $8,24714 claims |
| Sanofi-aventis U.S. LLCLantus | $91 | $1,27317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Flint
- Sajjad GulFlint$39K
- Henry MendozaFlint$29K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.